Why the study?
Does the NOS3 (Glu298Asp) or ACE (I/D) polymorphism alter endothelial cell sensitivity to glucose and 3-nitrotyrosine toxicity?
Does the NOS3 (Glu298Asp) or ACE (I/D) polymorphism alter endothelial cell sensitivity to glucose and 3-nitrotyrosine toxicity?
The NOS3 (Glu298Asp) polymorphism may be mechanistically involved in endothelial vulnerability to hyperglycemia, potentially contributing to diabetic vascular complications.
Answers are grounded in this paper and cite their sources.
Should not guide genotyping or therapy in diabetes; leaves open NOS3 role in human endothelial vulnerability pending validation.
The functional relevance of NOS3 and ACE genetic variations to endothelial cell function is largely unstudied. Here we tested the functional relevance of the NOS3 (Glu298Asp) polymorphism and ACE (I/D) polymorphism in endothelial cells in vitro. Our hypothesis was that these genetic polymorphisms alter endothelial cell sensitivity to glucose and 3-nitrotyrosine (3NT). Genotyped HUVECs were incubated with glucose, free 3NT or a combination of these two toxicants. Significant differences in glucose-induced cell death and free 3NT-induced cell death were observed among the NOS3 genotypes. Combined glucose/3NT caused increased toxicity among the NOS3 genotypes. No differences were observed among the ACE genotypes in their responses to glucose/3NT. These data demonstrate that the NOS3 genotype may be an important predictor of, or be mechanistically involved in, endothelial vulnerability, whereas the ACE I/D genotype is apparently less important. Thus this NOS3 genetic variation may play a role in vulnerability to endothelium-dependent diabetic vascular complications.
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: